Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT06079112 trial: what clinicians have said so far
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
- NCT06079112 ↗
- Recruiting
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT06079112 (9MW2821 plus toripalimab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06079112 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/II, Open-label, Single Arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- 9MW2821; Toripalimab
- Arms
- 9MW2821+Toripalimab · Experimental
- Enrollment
- 100 (estimated)
- Primary outcomes
- incidence of AE/SAE
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Start
- Sep 27, 2023
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06079112 · updated Sep 19, 2024